The Protein Kinase C Theta Type pipeline drugs market research report outlays comprehensive information on the Protein Kinase C Theta Type targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Protein Kinase C Theta Type pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Oncology, Immunology, Metabolic Disorders, and Dermatology which include the indications Unspecified Cancer, Breast Cancer, Rheumatoid Arthritis, Inflammation, Obesity, Type 2 Diabetes, and Atopic Dermatitis (Atopic Eczema). It also reviews key players involved in Protein Kinase C Theta Type targeted therapeutics development with respective active and dormant or discontinued products.
The Protein Kinase C Theta Type pipeline targets constitutes close to eight molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 1, 2, and 3 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Protein Kinase C Theta Type overview
Protein kinase C theta (PKC-θ) is an enzyme encoded by the PRKCQ gene. It mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-costimulated T-cells, is required for the activation of NF-kappa-B and JUN. It plays an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. It mediate inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1 which in turn blocks IRS1 tyrosine phosphorylation and downstream activation of the PI3K/AKT pathway.
For a complete picture of Protein Kinase C Theta Type’s drug pipeline, buy the report here.